We work on the best targets for patients
We have an exciting pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes – Solute Carriers, GPCRs, Inflammasome – with a focus on immunological and orphan diseases. We select targets with low translation risk through genetic association, pathway linked patient selection or immune signature stratification.
Click Target For More Info
|Target||Type||Indication||Discovery||Lead ID||Lead Optimisation||Preclinical|
|MC2||GPCR||Orphan endocrine disorders|
|Gasdermin||Intracellular complexes||Broad immunology|
|SLC15A4||Solute carriers||Lupus and other IFN-opathies|
|KCC2||Solute carriers||Epilepsy including rare epilepsy disorders|
Additional target validation
Insurmountable ACTH antagonism for a best-in-class profile in rare endocrine disorders.
First-in-class Gasdermin D inhibitors – a pipeline in a product.
First-in-class solute carrier inhibitor against a highly validated target in Lupus and other IFN-opathies
First-in-class solute carrier activator reducing seizures in epilepsy including rare epilepsies
First-in-class molecules driving novel anti-inflammatory biology in Inflammatory Bowel Disease.